Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | CES1 | P23141 | 4/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.37 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.34 |
| ▸ | PRKCG | P05129 | 2/20 | 0.34 |
| ▸ | PRKCB | P05771 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14308138 | 0.79 | EPHX2 (0.44) | CES2THRBBLMCA2EPHX2 | |
| SCHEMBL30233747 | 0.79 | EPHX2 (0.44) | CES2THRBBLMCA2EPHX2 | |
| SCHEMBL7602668 | 0.74 | CES2 (0.45) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL29462497 | 0.74 | CES2 (0.45) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL24370114 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL199121 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL199011 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL867379 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL198723 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 | |
| SCHEMBL24362145 | 0.73 | THRB (0.57) | CES2CTSLCTSBGMNNTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | CES2 1505/4885CTSL 414/4885CTSB 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.